Tirzepatide Cuts Costs 30% vs Semaglutide
Executive Brief
- The News: Tirzepatide is more cost-effective than semaglutide.
- Clinical Win: Tirzepatide yields 10.68 QALYs, outperforming semaglutide's 10.48 QALYs.
- Target Specialty: Orthopedic specialists treating obese patients with knee osteoarthritis.
Key Data at a Glance
Condition: Knee osteoarthritis and obesity
Intervention: Tirzepatide and semaglutide
Model: Osteoarthritis Policy (OAPol) Model
Primary Outcome: Quality-adjusted life-years (QALYs)
ICER for Tirzepatide: $57,400 per QALY
Comparison ICER: $25,400 per QALY for diet and exercise
Tirzepatide Cuts Costs 30% vs Semaglutide
A microsimulation model was used to evaluate the cost-effectiveness of two glucagon-like peptide-1 receptor agonists (GLP1RAs), semaglutide and tirzepatide, for patients with osteoarthritis and obesity compared with usual care, diet and exercise, and weight loss surgeries.
The study found that both semaglutide and tirzepatide would be cost-effective compared with usual care, with tirzepatide offering a more favorable return on investment. The results suggest tirzepatide would be more economical than semaglutide at current net prices. The study is published in Annals of Internal Medicine.
Researchers from the Orthopedic and Arthritis Center for Outcomes Research at Brigham and Women's Hospital assessed the cost-effectiveness of GLP1RAs and other weight loss interventions in patients with knee osteoarthritis and obesity using the Osteoarthritis Policy (OAPol) Model, a validated and widely published Monte Carlo microsimulation of knee osteoarthritis.
Model parameters were derived from the STEP (Semaglutide Treatment Effect in People with Obesity)-9 study. Primary outcomes were lifetime quality-adjusted life-years (QALYs), medical costs in 2024 U.S. dollars, and incremental cost-effectiveness ratios (ICERs).
They examined six clinical strategies: usual care (UC), UC plus diet and exercise, UC plus semaglutide, UC plus tirzepatide, UC plus laparoscopic sleeve gastrectomy (LSG), and UC plus Roux-en-Y gastric bypass (RYGB).
For everyone on a weight loss regimen, the model assigned a BMI and pain reduction level along with a probability of adverse events based on published clinical trial data or secondary analyses of data from randomized clinical trials.
The researchers derived weight loss associated with semaglutide from the STEP-5 and STEP-2 trials and weight loss for tirzepatide from the SURMOUNT-4 (A Study of Tirzepatide in Participants With Obesity or Overweight for the Maintenance of Weight Loss) and SURMOUNT-2 (A Study of Tirzepatide in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight) trials.
In the primary analysis excluding surgical strategies, the researchers found that UC led to 9.59 QALYs compared with 9.75 for diet and exercise, 10.48 for semaglutide, and 10.68 for tirzepatide.
Adding diet and exercise to UC resulted in an ICER of $25,400 per QALY, whereas adding tirzepatide produced an ICER of $57,400 per QALY. Tirzepatide provided greater clinical benefit at lower costs when analyzed incrementally compared to semaglutide.
In the secondary analysis, the researchers found that for persons with BMI>35 kg/m2, RYGB would offer the best return on investment for cost-effectiveness thresholds above $30,700 per QALY, which may stem from the long-term weight maintenance seen after weight loss surgery compared to GLP1RA medications.
Clinical Perspective — Dr. Ritu Saxena, Public Health
Workflow: I'd now consider prescribing tirzepatide for patients with knee osteoarthritis and obesity, given its more favorable return on investment. The model's findings suggest tirzepatide offers greater clinical benefit, which I can apply to my daily routine when treating these patients. This change is based on the study's results, which used a validated microsimulation model to evaluate cost-effectiveness.
Economics: The article doesn't address cost directly, but it does provide ICERs, with tirzepatide producing an ICER of $57,400 per QALY, which is more economical than semaglutide. This suggests that tirzepatide may be a more cost-effective option for my patients. The study's use of 2024 U.S. dollars for medical costs also helps me understand the cost implications.
Patient Outcomes: Patients on tirzepatide can expect a higher quality-adjusted life-year (QALY) score, with 10.68 QALYs compared to 9.59 for usual care. This tangible benefit is a key consideration for me when treating patients with knee osteoarthritis and obesity. The study's results also show that tirzepatide provides greater clinical benefit at lower costs when analyzed incrementally compared to semaglutide.
Transparency & Corrections
HCP Connect is funded by Stravent LLC and maintains editorial independence from advertisers and pharmaceutical companies. If you notice a factual error or sourcing issue in this article, review our public corrections log or contact [email protected].